Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the CDCA5 that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a metastatic or postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from CDCA5, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.本案揭示抗癌的胜肽疫苗。特別是，本案提供誘發CTLs之衍生自CDCA5的單離的抗原決定位胜肽，因此適合用於癌症免疫治療的內容。本案更提供編碼此胜肽的多核苷酸及包含上述胜肽或多核苷酸為活性劑之醫藥組成物。本案更提供具有CTL誘導能力的抗原呈現細胞與標靶上述胜肽的CTLs，以及誘導抗原呈現細胞或CTL的方法。而且，本案提供使用本案之衍生自CDCA5之抗原決定位胜肽、編碼此胜肽之多核苷酸、呈現此胜肽之抗原呈現細胞、或醫藥組成物，治療及/或預防(如預防)癌症(腫瘤)、及/或轉移的或術後的復發之方法，以及誘導CTLs的方法、誘導抗腫瘤免疫性的方法。
